Generic Name and Formulations:
Moexipril HCl, hydrochlorothiazide; 7.5mg/12.5mg, 15mg/12.5mg, 15mg/25mg; scored tabs.
Various generic manufacturers
Indications for Moexipril/Hydrochlorothiazide:
Hypertension (not for initial therapy).
Take 1 hour before a meal. Switching from monotherapy with either component: 1 tab once daily; adjust at 2–3 week intervals; usual max 30mg/50mg per day. Or, substitute for individually-titrated components.
History of ACEI-associated angioedema. Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment (CrCl ≤40mL/min): not recommended. Discontinue if angioedema, laryngeal edema, jaundice, or marked elevation of hepatic enzymes occurs. Renal or hepatic dysfunction. Salt/volume depletion. CHF. Ischemic heart disease. Aortic or renal artery stenosis. Cerebrovascular disease. Dialysis (esp. high-flux membrane). Surgery. Diabetes. Gout. Asthma. Postsympathectomy. Monitor WBC counts in renal or collagen vascular disease. SLE. Acute myopia and secondary angle-closure glaucoma. Monitor electrolytes and renal function. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
ACE inhibitor + diuretic.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May cause hyperkalemia with K+ sparing diuretics, K+ supplements, or K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH, amphotericin B. May increase lithium, digitalis, diazoxide toxicity. Alcohol, CNS depressants may increase orthostatic hypotension. Adjust antidiabetic, antigout medications. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. May interfere with parathyroid tests. Reduced absorption with cholestyramine and colestipol resins. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Cough, dizziness, fatigue, headache, hyperuricemia, electrolyte disturbances, hyperglycemia, rash, facial flushing, GI upset, angioedema (eg, intestinal), orthostatic hypotension, neutropenia; rare: hepatic failure.
Formerly known under the brand name Uniretic.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|